GlassScriptPhysician profile
Sheemain Asaria
NPI 1154462000
$2,853.57
in general payments reported to CMS, 2019-2025
25 companies · $461 in 2025
The $461 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $111 · 2021: $407 · 2022: $445 · 2023: $656 · 2024: $498 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.24 | 2019-2024 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $299.38 | 2021-2025 | Aptima |
| Exeltis, USA INC. | $293.20 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $282.39 | 2019-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $241.93 | 2022-2025 | |
| Biogen, INC. | $143.60 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $140.88 | 2022-2023 | Veozah |
| Organon LLC | $140.85 | 2021-2025 | Nexplanon |
| Pfizer INC. | $128.32 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $98.79 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $98.75 | 2019-2022 | |
| Therapeuticsmd, INC. | $89.78 | 2019-2022 | |
| Millicent US INC | $84.19 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Myovant Sciences INC. | $69.86 | 2021-2022 | |
| Amgen INC. | $58.25 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $55.26 | 2023-2025 | Exparel |
| Agile Therapeutics, INC. | $48.53 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $44.36 | 2019-2024 | Gardasil, Gardasil 9 |
| Avion Pharmaceuticals | $43.86 | 2023 | Balcoltra |
| Duchesnay USA Incorporated | $27.85 | 2019 | |
| Meditrina | $22.94 | 2022-2023 | |
| Vertical Pharmaceuticals, LLC | $18.22 | 2019 | |
| Coopersurgical, INC. | $18.11 | 2024 | Paragard T 380a |
| Lupin INC. | $17.97 | 2021 | |
| Convatec INC. | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheemain Asaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.